MA54551A - Composés d'imidazopyridazine et d'imidazopyridine utilisés en tant qu'inhibiteurs de la kinase 2 de type récepteur de l'activine - Google Patents
Composés d'imidazopyridazine et d'imidazopyridine utilisés en tant qu'inhibiteurs de la kinase 2 de type récepteur de l'activineInfo
- Publication number
- MA54551A MA54551A MA054551A MA54551A MA54551A MA 54551 A MA54551 A MA 54551A MA 054551 A MA054551 A MA 054551A MA 54551 A MA54551 A MA 54551A MA 54551 A MA54551 A MA 54551A
- Authority
- MA
- Morocco
- Prior art keywords
- imidazopyridazine
- inhibitors
- compounds used
- receptor type
- activin receptor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862782994P | 2018-12-20 | 2018-12-20 | |
| US201962935891P | 2019-11-15 | 2019-11-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA54551A true MA54551A (fr) | 2021-10-27 |
Family
ID=69467674
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA054551A MA54551A (fr) | 2018-12-20 | 2019-12-19 | Composés d'imidazopyridazine et d'imidazopyridine utilisés en tant qu'inhibiteurs de la kinase 2 de type récepteur de l'activine |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US11459329B2 (fr) |
| EP (1) | EP3898627A1 (fr) |
| JP (2) | JP7414827B2 (fr) |
| KR (1) | KR20210116488A (fr) |
| CN (1) | CN114787160A (fr) |
| AU (1) | AU2019401649A1 (fr) |
| BR (1) | BR112021011948A2 (fr) |
| CA (1) | CA3124088A1 (fr) |
| CL (1) | CL2021001656A1 (fr) |
| CO (1) | CO2021008117A2 (fr) |
| CR (1) | CR20210336A (fr) |
| EC (1) | ECSP21044843A (fr) |
| IL (1) | IL284139A (fr) |
| MA (1) | MA54551A (fr) |
| MX (1) | MX2021007426A (fr) |
| PE (1) | PE20220277A1 (fr) |
| PH (1) | PH12021551446A1 (fr) |
| SG (1) | SG11202106582YA (fr) |
| TW (1) | TW202039502A (fr) |
| WO (1) | WO2020132197A1 (fr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019401649A1 (en) * | 2018-12-20 | 2021-07-08 | Incyte Corporation | Imidazopyridazine and imidazopyridine compounds as inhibitors of activin receptor-like kinase-2 |
| TW202214660A (zh) | 2020-06-12 | 2022-04-16 | 美商英塞特公司 | 咪唑并嗒嗪化合物及其用途 |
| WO2023066204A1 (fr) * | 2021-10-18 | 2023-04-27 | 上海美悦生物科技发展有限公司 | Inhibiteur de sik, composition de celui-ci, son procédé de préparation et son utilisation |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ303572B6 (cs) | 2000-06-28 | 2012-12-12 | Smithkline Beecham P. L. C. | Jemne rozmelnený prostredek a zpusob jeho prípravy |
| JP2005343889A (ja) | 2004-05-06 | 2005-12-15 | Taisho Pharmaceut Co Ltd | イミダゾピリジン誘導体 |
| PT1812440E (pt) | 2004-11-04 | 2011-01-25 | Vertex Pharma | Pirazolo[1,5-a]pirimidinas úteis enquanto inibidores de proteínas cinases |
| ES2689444T3 (es) * | 2006-11-22 | 2018-11-14 | Incyte Holdings Corporation | Imidazotriazinas e imidazopirimidinas como inhibidores de la quinasa |
| ATE522249T1 (de) | 2007-07-26 | 2011-09-15 | Novartis Ag | Organische verbindungen |
| ES2393430T3 (es) * | 2007-10-17 | 2012-12-21 | Novartis Ag | Derivados de imidazo[1,2-A]-piridina útiles como inhibidores de ALK |
| EP2453882A1 (fr) | 2009-07-14 | 2012-05-23 | Beth Israel Deaconess Medical Center, Inc. | Procédés d augmentation de la prolifération hépatique |
| WO2012013713A2 (fr) * | 2010-07-28 | 2012-02-02 | Bayer Pharma Aktiengesellschaft | Imidazo[1,2-b]pyridazines substituées |
| KR102092988B1 (ko) | 2012-09-28 | 2020-03-25 | 벤더르빌트 유니버시티 | 선택성 bmp 저해제로써 융합된 헤테로 고리 화합물들 |
| MX2015005375A (es) | 2012-11-07 | 2015-07-21 | Hoffmann La Roche | Compuestos de triazolo. |
| WO2014160203A2 (fr) * | 2013-03-14 | 2014-10-02 | The Brigham And Women's Hospital, Inc. | Inhibiteurs de bmp et leurs procédés d'utilisation |
| EP3365340B1 (fr) | 2015-10-19 | 2022-08-10 | Incyte Corporation | Composés hétérocycliques utilisés comme immunomodulateurs |
| MD3377488T2 (ro) | 2015-11-19 | 2023-02-28 | Incyte Corp | Compuși heterociclici ca imunomodulatori |
| EP3390361B1 (fr) | 2015-12-17 | 2022-03-16 | Incyte Corporation | Dérivés de n-phényl-pyridine-2-carboxamide et leur utilisation en tant que modulateurs des interactions protéine/protéine pd-1/pd-l1 |
| SG11201805300QA (en) | 2015-12-22 | 2018-07-30 | Incyte Corp | Heterocyclic compounds as immunomodulators |
| ES2906460T3 (es) | 2016-05-06 | 2022-04-18 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
| US20170342060A1 (en) | 2016-05-26 | 2017-11-30 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| CA3028685A1 (fr) | 2016-06-20 | 2017-12-28 | Incyte Corporation | Composes heterocycliques utilises comme immunomodulateurs |
| US20180016260A1 (en) | 2016-07-14 | 2018-01-18 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| CA3033755A1 (fr) | 2016-08-17 | 2018-03-01 | Children's Hospital Medical Center | Composes, compositions, procedes pour le traitement de maladies et procedes pour la preparation de composes |
| ES2941716T3 (es) | 2016-08-29 | 2023-05-25 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
| WO2018053126A1 (fr) * | 2016-09-14 | 2018-03-22 | Vanderbilt University | Inhibition de la signalisation bmp, composés, compositions et leurs utilisations |
| HRP20221216T1 (hr) | 2016-12-22 | 2022-12-23 | Incyte Corporation | Derivati tetrahidro imidazo[4,5-c]piridina kao induktori internalizacije pd-l1 |
| US20180179201A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| WO2018119263A1 (fr) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Composés hétérocycliques utilisés en tant qu'inducteurs de l'internalisation de pd-l1 |
| ES2934230T3 (es) | 2016-12-22 | 2023-02-20 | Incyte Corp | Derivados de benzooxazol como inmunomoduladores |
| US20180179179A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| CA3047991A1 (fr) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Composes heteroaromatiques bicycliques utilises en tant qu'immunomodulateurs |
| US20200054643A1 (en) | 2017-01-18 | 2020-02-20 | Vanderbilt University | Fused heterocyclic compounds as selective bmp inhibitors |
| WO2018165569A1 (fr) * | 2017-03-10 | 2018-09-13 | Rutgers, The State University Of New Jersey | Composés et méthodes thérapeutiques |
| PE20200008A1 (es) | 2017-03-30 | 2020-01-06 | Hoffmann La Roche | Isoquinolinas como inhibidores de hpk1 |
| AU2019401649A1 (en) * | 2018-12-20 | 2021-07-08 | Incyte Corporation | Imidazopyridazine and imidazopyridine compounds as inhibitors of activin receptor-like kinase-2 |
-
2019
- 2019-12-19 AU AU2019401649A patent/AU2019401649A1/en active Pending
- 2019-12-19 SG SG11202106582YA patent/SG11202106582YA/en unknown
- 2019-12-19 CN CN201980092367.1A patent/CN114787160A/zh active Pending
- 2019-12-19 CR CR20210336A patent/CR20210336A/es unknown
- 2019-12-19 TW TW108146732A patent/TW202039502A/zh unknown
- 2019-12-19 BR BR112021011948-5A patent/BR112021011948A2/pt unknown
- 2019-12-19 JP JP2021535854A patent/JP7414827B2/ja active Active
- 2019-12-19 US US16/720,935 patent/US11459329B2/en active Active
- 2019-12-19 WO PCT/US2019/067403 patent/WO2020132197A1/fr unknown
- 2019-12-19 MA MA054551A patent/MA54551A/fr unknown
- 2019-12-19 MX MX2021007426A patent/MX2021007426A/es unknown
- 2019-12-19 EP EP19848840.5A patent/EP3898627A1/fr active Pending
- 2019-12-19 CA CA3124088A patent/CA3124088A1/fr active Pending
- 2019-12-19 KR KR1020217022783A patent/KR20210116488A/ko unknown
- 2019-12-19 PE PE2021001046A patent/PE20220277A1/es unknown
-
2021
- 2021-06-17 IL IL284139A patent/IL284139A/en unknown
- 2021-06-18 PH PH12021551446A patent/PH12021551446A1/en unknown
- 2021-06-18 CL CL2021001656A patent/CL2021001656A1/es unknown
- 2021-06-21 CO CONC2021/0008117A patent/CO2021008117A2/es unknown
- 2021-06-21 EC ECSENADI202144843A patent/ECSP21044843A/es unknown
-
2022
- 2022-06-09 US US17/836,602 patent/US20220315595A1/en active Pending
-
2023
- 2023-12-28 JP JP2023222944A patent/JP2024045155A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| ECSP21044843A (es) | 2021-09-30 |
| US20200199131A1 (en) | 2020-06-25 |
| US11459329B2 (en) | 2022-10-04 |
| JP2024045155A (ja) | 2024-04-02 |
| AU2019401649A1 (en) | 2021-07-08 |
| CL2021001656A1 (es) | 2021-12-17 |
| US20220315595A1 (en) | 2022-10-06 |
| JP7414827B2 (ja) | 2024-01-16 |
| TW202039502A (zh) | 2020-11-01 |
| SG11202106582YA (en) | 2021-07-29 |
| PH12021551446A1 (en) | 2021-12-06 |
| BR112021011948A2 (pt) | 2021-09-08 |
| CA3124088A1 (fr) | 2020-06-25 |
| MX2021007426A (es) | 2021-09-08 |
| EP3898627A1 (fr) | 2021-10-27 |
| CR20210336A (es) | 2021-12-06 |
| CO2021008117A2 (es) | 2021-09-20 |
| PE20220277A1 (es) | 2022-02-25 |
| WO2020132197A1 (fr) | 2020-06-25 |
| CN114787160A (zh) | 2022-07-22 |
| KR20210116488A (ko) | 2021-09-27 |
| IL284139A (en) | 2021-08-31 |
| JP2022514650A (ja) | 2022-02-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA53487A (fr) | Composés pyrazolo[3,4-b]pyridine utilisés en tant qu'inhibiteurs de kinases tam et met | |
| MA49888A (fr) | Composés macrocycliques utilisés en tant qu'inhibiteurs de kinase ros1 | |
| MA51846A (fr) | Composés hétérocycliques utilisés en tant qu'inhibiteurs de kinases | |
| MA52360A (fr) | Dérivés de 2-amino-pyridine ou de 2-amino-pyrimidine utilisés en tant qu'inhibiteurs de kinases dépendantes des cyclines | |
| MA49570A (fr) | Composés bicycliques pyrazolo et triazolo utilisés en tant qu'inhibiteurs de kinase jak | |
| MA53675A (fr) | Composés substitués de pyrazolo[1,5-a]pyridine en tant qu'inhibiteurs de la kinase ret | |
| MA52486A (fr) | Pyridazinones utilisés en tant qu'inhibiteurs de parp7 | |
| MA54076A (fr) | 2-amino-n-hétéroaryl-nicotinamides utilisés en tant qu'inhibiteurs de nav1.8 | |
| MA47013A (fr) | Composés benzolactames utilisés en tant qu'inhibiteurs de protéine kinase | |
| MA47099A (fr) | Composés hétéroaromatiques bicycliques utilisés en tant qu'immunomodulateurs | |
| MA54551A (fr) | Composés d'imidazopyridazine et d'imidazopyridine utilisés en tant qu'inhibiteurs de la kinase 2 de type récepteur de l'activine | |
| MA45375A (fr) | Composés hétérocycliques utilisés en tant qu'agents antibacteriens | |
| MA43169A (fr) | Composés hétérocycliques utilisés en tant qu'inhibiteurs de pi3k-gamma | |
| MA41551A (fr) | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 | |
| MA55198A (fr) | Composés tricycliques fusionnés utiles en tant qu'agents anticancéreux | |
| MA52189A (fr) | Benzothiophènes et composés associés utilisés en tant qu'agonistes de sting | |
| MA42919A (fr) | Composés bicycliques utilisés en tant qu'inhibiteurs d'atx | |
| MA42918A (fr) | Composés bicycliques utilisés en tant qu'inhibiteurs d'atx | |
| MA51438A (fr) | Composés hétérocycliques utilisés en tant qu'inhibiteurs de lsd1 | |
| MA49956A (fr) | Composés de pyrimidine utilisés en tant qu'inhibiteurs de kinase jak | |
| MA45377A (fr) | Composés hétérocycliques en tant qu'agents antibacteriens | |
| MA51429A (fr) | Dérivés amino-fluoropipéridines utilisés en tant qu'inhibiteur de kinase | |
| MA47086A (fr) | Dérivés de dihydropyrimidine-carboxamide bicycliques utilisés en tant qu'inhibiteurs de rho-kinase | |
| MA53220A (fr) | Nouveaux composés hétérocycliques utilisés en tant qu'inhibiteurs de monoacylglycérol lipase | |
| MA50375A (fr) | Compositions contenant des composés substitués de [1,2,4]triazolo[1,5-a]pyrimidine-7-yl utilisés en tant qu'inhibiteurs pde2 |